Ying Guo

Summary

Affiliation: University of Kansas Medical Center
Country: USA

Publications

  1. doi Repeated administration of berberine inhibits cytochromes P450 in humans
    Ying Guo
    Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Xiangya School of Medicine, 110 Xiang Ya Road, Changsha, Hunan 410078, People s Republic of China
    Eur J Clin Pharmacol 68:213-7. 2012
  2. pmc Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice
    Ying Guo
    Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan, People s Republic of China
    J Ethnopharmacol 138:111-8. 2011
  3. doi CYP2D plays a major role in berberine metabolism in liver of mice and humans
    Ying Guo
    Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University Changsha, Hunan, People s Republic of China
    Xenobiotica 41:996-1005. 2011
  4. pmc Searching the cytochrome p450 enzymes for the metabolism of meranzin hydrate: a prospective antidepressant originating from chaihu-shugan-san
    Xi Huang
    Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, China Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, 110 Xiangya Road, Changsha, Hunan 410078, China Laboratory of Ethnopharmacology, Institute of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, 410008 Changsha, China
    PLoS ONE 9:e113819. 2014

Collaborators

  • Wei Zhang
  • Xiaochao Ma
  • Xi Huang
  • Min Luo
  • Yi Cheng Wang
  • Yang Wang
  • Dong Li Hu
  • Dong Sheng Ouyang
  • Wei Hua Huang
  • Yao Chen
  • Zhi rong Tan
  • Jian Xiao
  • Jing Bo Peng

Detail Information

Publications4

  1. doi Repeated administration of berberine inhibits cytochromes P450 in humans
    Ying Guo
    Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Xiangya School of Medicine, 110 Xiang Ya Road, Changsha, Hunan 410078, People s Republic of China
    Eur J Clin Pharmacol 68:213-7. 2012
    ..Many studies have reported interactions between berberine-containing products and cytochromes P450 (CYPs), but little is known about whether berberine alters CYP activities in humans, especially after repeated doses...
  2. pmc Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice
    Ying Guo
    Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, 410078 Hunan, People s Republic of China
    J Ethnopharmacol 138:111-8. 2011
    ..It is also widely used in Asian countries for diabetes, hypertension, and hypercholesterolemia therapy...
  3. doi CYP2D plays a major role in berberine metabolism in liver of mice and humans
    Ying Guo
    Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University Changsha, Hunan, People s Republic of China
    Xenobiotica 41:996-1005. 2011
    ..CYP2D plays a major role in berberine biotransformation, therefore, CYP2D6 pharmacogenetics and potential drug-drug interactions should be considered when berberine is used...
  4. pmc Searching the cytochrome p450 enzymes for the metabolism of meranzin hydrate: a prospective antidepressant originating from chaihu-shugan-san
    Xi Huang
    Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, China Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, 110 Xiangya Road, Changsha, Hunan 410078, China Laboratory of Ethnopharmacology, Institute of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, 87 Xiangya Road, 410008 Changsha, China
    PLoS ONE 9:e113819. 2014
    ..The results suggested that MH was simultaneously a substrate and an inhibitor of CYP1A2 and CYP2C9, and MH had the potential to perpetrate drug-drug interactions with other CYP1A2 and CYP2C19 substrates. ..